Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

#AAD26: Tanabe’s Phase 3 win for drug targeting rare diseases that cause pain upon light exposure

Published

on

Tanabe Pharma unveiled positive data from a Phase 3 trial of its oral drug for a pair of rare diseases, its first major clinical milestone after it was acquired by Bain Capital …

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b miss

Published

on

The anti-TL1A antibody from Merck’s 2023 Prometheus buy delivered positive mid-stage results in a skin condition but failed in a certain type of lung disease, the Big Pharma revealed alongside second-quarter earnings.

Continue Reading

Uncategorized

BioNTech cuts sales forecast on slumping demand for COVID-19 vaccine

Published

on

Lower vaccine demand across every market and more acute pressures in Germany led BioNTech to lower the midpoint of its sales outlook by almost 20%.

Continue Reading

Uncategorized

J&J pharma leader to retire; Krystal slumps on gene therapy miss

Jennifer Taubert will step down after a lengthy run leading J&J’s pharmaceutical business. Elsewhere, pricing issues hampered what Wall Street analysts view as an otherwise strong gene therapy launch.

Read More

Published

on

Jennifer Taubert will step down after a lengthy run leading J&J’s pharmaceutical business. Elsewhere, pricing issues hampered what Wall Street analysts view as an otherwise strong gene therapy launch.

Read More

Continue Reading
Advertisement

Trending